Fintel reports that on February 4, 2025, Piper Sandler downgraded their outlook for Amphastar Pharmaceuticals (NasdaqGS:AMPH) ...

Piper Sandler adjusted its stance on Amphastar Pharmaceuticals (NASDAQ:AMPH), downgrading the company's stock rating from Overweight to Neutral and significantly reducing the price target to $36.00 ...

Piper Sandler downgraded Amphastar (AMPH) to Neutral from Overweight with a price target of $36, down from $66. The firm noted that shares of ...

In a report released today, Jason Gerberry from Bank of America Securities reiterated a Hold rating on Amphastar Pharmaceuticals (AMPH – ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

So, let’s take a look at the Value Grade for all of our stocks. Amphastar Pharmaceuticals, Inc. stock has a Value Grade of B. Takeda Pharmaceutical Company Limited stock has a Value Grade of B.

Ever wonder which ETFs do the best job at beating the benchmark index? This list is a good place to start.

Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and ...